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Somatic L1 retrotransposition events have been shown to occur in epithelial cancers. Here, we attempted to determine how
early somatic L1 insertions occurred during the development of gastrointestinal (GI) cancers. Using L1-targeted resequencing
(L1-seq), we studied different stages of four colorectal cancers arising from colonic polyps, seven pancreatic carcinomas, as
well as seven gastric cancers. Surprisingly, we found somatic L1 insertions not only in all cancer types and metastases but also
in colonic adenomas, well-known cancer precursors. Some insertions were also present in low quantities in normal GI tissues,
occasionally caught in the act of being clonally fixed in the adjacent tumors. Insertions in adenomas and cancers numbered
in the hundreds, and many were present in multiple tumor sections, implying clonal distribution. Our results demonstrate
that extensive somatic insertional mutagenesis occurs very early during the development of GI tumors, probably before
dysplastic growth.
[Supplemental material is available for this article.]
Somatic mobilization of retroelements in the cancer genome has
only recently been established as a widespread mutational phe-
nomenon. In particular, Long INterspersed Element (LINE)-1
(L1)-mediated retrotransposition has been observed mostly in ep-
ithelial cancers. Somatic human-specific L1 (L1Hs) insertions are
most abundant in these cancers, but L1-mediated Alu, SVA, and
processed pseudogene insertions have also been detected (Iskow
et al. 2010; Lee et al. 2012; Solyom et al. 2012; Ewing et al. 2013;
Shukla et al. 2013; Cooke et al. 2014; Helman et al. 2014;
Pitkanen et al. 2014; Tubio et al. 2014). L1s are autonomous
mobile elements that comprise 17% of the human genome and
retrotranspose by a “copy and paste”mechanism via an RNA inter-
mediate. This process can lead to insertional mutagenesis and
genetic instability (Goodier and Kazazian 2008). Potentially etio-
logical L1 insertions have been reported in APC (Miki et al. 1992)
and PTEN exons (Helman et al. 2014) in colorectal and endometri-
al cancer, respectively, and insertions of unknown significance
have been found in numerous other cancer driver genes in a vari-
ety ofmalignancies (Iskow et al. 2010; Lee et al. 2012; Solyom et al.
2012; Ewing et al. 2013; Shukla et al. 2013; Cooke et al. 2014;
Helman et al. 2014; Pitkanen et al. 2014; Tubio et al. 2014;
Paterson et al. 2015). In a study of somatic retrotransposition dur-
ing the evolution of prostate and lung cancer, Tubio et al. (2014)
found evidence of insertions occurring during cancer develop-
ment. Beyond this work, the timing of retrotransposition in cancer
development has not been analyzed previously.
Results
Timing and distribution of somatic L1 insertions
in GI cancers
Here, we studied the timing of L1Hs integration events in 30 tu-
mors of different developmental stages from 18 GI cancer patients
(Table 1). We studied DNA from four colorectal cancer patients
previously diagnosed with colonic polyps (one hyperplastic
polyp and four adenomas, one of which contained high-grade dys-
plasia), seven patients with invasive pancreatic carcinoma, one of
whom also had a pancreatic intraepithelial neoplasia (PanIN, a
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precancerous lesion), and from seven patients with primary gastric
cancer.Matched normal samples were of the same tissue type from
which the tumors originated, and multiple metastases were also
available in eight cases. Next-generation L1-resequencing (L1-
seq) (Ewing and Kazazian 2010; Solyom et al. 2012) was carried
out on DNA from dissected tissues. We also studied somatic
Table 1. PCR-verified and Sanger-sequenced somatic L1 insertions
(Top panel) Four patients with colon polyps and cancers. All polyps were adenomas with the exception of the polyp in patient 1BV, which was hyper-
plastic. However, note that the cancer in patient 3BV was reclassified as adenoma with high-grade dysplasia (a state which is in between an adenoma-
tous polyp and a carcinoma). Thus, from patient 3BV, two independent adenomas were sequenced. All primary cancers were adenocarcinomas.
Metastases were available for L1-seq from patients 2BV and 4BV. For patients 1BV and 3BV, two sections of the primary cancer were subjected to L1-
seq. (Middle panel) Seven patients with pancreatic carcinomas and metastases. The following five patient samples were genotyped by both L1-seq and
TIP-seq, a method derived from TIP-chip (Huang et al. 2010; Rodic´ et al. 2015): A43, A55, A57, A82, and A146. Sixteen insertions found by TIP-seq
overlap potential insertion sites found via L1-seq (sites with “1” in the column “TIP-seq” in Supplemental Table 2c). Of these, six had been previously
validated based on the L1-seq annotation (sites with “1” in the column “TIP-seq” and with “0” in the column “Added by TIP-seq”). Thus, 10 additional
insertions were found by both L1-seq and TIP-seq independently (sites with a “1” in the column “Added by TIP-seq” in Supplemental Table 2c). These
10 sites correspond to the 10 sites in the row “L1-seq validated by TIP-seq” in Table 1. (Bottom panel) Seven patients with gastric carcinomas. Blue:
very early insertion events in premalignant lesions (note that the polyp in patient 3BV is an adenoma with high grade dysplasia); red: potentially clonal
and likewise early insertion events, but the pre-malignant lesion from which the primary cancer evolved is unavailable. (N) Normal epithelium, (N1)
normal epithelium section 1, (N2) normal epithelium section 2, (P) polyp, (C) primary cancer, (C1) primary cancer section 1, (C2) primary cancer
section 2, (M) metastasis. The results of L1-seq, distribution of the pooled samples in sequencing lanes, and clinical details of the patients are in
Supplemental Table 2. As we did not attempt validation on all putative somatic insertion sites, we have included the number of possible additional in-
sertions predicted based on the validation rate of tested sites (Supplemental Fig. 1).
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L1Hs integration events in eight testicular germ cell tumors
(TGCT) andmatched blood of seven of these patients with familial
TGCT. Sample characteristics and pathological data of each tumor
type are described in Supplemental Table S2, sheets S2j, S2n, S2p,
and S2t, respectively.
Altogether, 104 somatic heterozygous L1Hs insertions were
validated by PCR and Sanger sequencing in the 18 GI cancer pa-
tients, while only one insertion validated in the seven TGCT pa-
tients (Table 1; Figs. 1, 2; Supplemental Data 1–4; Supplemental
Table 2). Our major finding is that somatic L1 insertions occur in
certain precancerous lesions. We also find that pancreatic and
stomach cancer are permissive for L1 mobilization (Table 1; Fig.
2; Supplemental Table 2). Of 24 insertions validated in pancreatic
cancers, 13 (54%) were present in two different sections of the pri-
mary cancers and in the matched liver metastases, signifying early
occurring insertions. Similarly, of 23 insertions validated in gastric
cancers, 18 (78%) were present in two independent tumor sec-
tions. In addition, out of the total of 57 validated insertions in co-
lorectal cancer, we were able to analyze 43 in two to four sections
of the same colorectal cancers and in two sections of the high-
grade dysplastic adenoma of patient 3BV. Of these 43, 42 (98%)
were present in all primary and metastatic cancer sections (Figs.
2, 3A). Surprisingly, of 57 validated somatic insertions in the colon
tumors, 29 (50%) were detected exclusively in adenomas. As vali-
dation was attempted on a subset of insertions, we sought to ob-
tain an estimate for how many insertions might validate across
the entire data set based on peak characteristics and the empirical
validation rate across various tissues. In total, we expect that
hundreds of additional insertions would validate in these GI tu-
mor cases (Table 1; Supplemental Fig. 1). However, with additional
validations focused on smaller peak sizes (i.e., those represented by
10 or fewer read mappings), the expected number of insertions
may increase dramatically, to well above 1000.
We observed evidence of clonal insertions in primary colorec-
tal and pancreatic cancer-metastasis cases, where 23 of 27 (85%)
somatic insertions in the primary cancers were present in their
Figure 1. Genomic distribution of L1 insertions in GI tumors. (A) The genomic distribution of reference (light blue histogram) (Supplemental Table 3) and
putative nonreference L1 insertions (light red histogram) (Supplemental Table 4) in colon cancer cases is shown as a density plot binned into 10-Mbp
intervals across the genome. Somatic insertions validated by PCR and capillary sequencing (Supplemental Table 2) are shown on the outside. The
tissue distribution for somatic insertions is shown according to the following key (see Table 1 for counts and Supplemental Table 2 for further details
on insertion sites): (C) primary cancer, (M) metastasis, (P) polyp, (N) normal colon. (B,C ) Shown similarly for pancreatic cancer samples in B and gastric
cancer samples in C.
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paired metastases. The clonal relationship of primary colon can-
cers and their metastases is corroborated by their comparable
CNV patterns by SNP Array 6.0 data analysis (Supplemental Fig.
2). In contrast, the polyps always originated at some distance
from their matched cancers, precluding the possibility that the
sampled cancers arose from the sampled polyps. In agreement,
no shared insertions have been validated between polyps and co-
lon cancers (Table 1).
The fact that half of the total validated insertions (29/57) in
colon tumors were found in precancerous lesions also implies
that these insertions occurred earlier, either at the dysplastic stage
or even in histologically normal cells. Indeed, we detected a
somatic insertion in a histologically normal colon sample of pa-
tient 2BV exclusively with two-stage nested PCR, suggesting low
abundance of the insertion. The L1was not present in normal liver
tissue, ruling out germline status or loss-of-heterozygosity (LOH)
in the tumors (Fig. 2C). Importantly, we also detected two inser-
tions that were abundantly present in two gastric cancer sections
(detectable by both conventional and nested PCR) and were also
present in two adjacent histologically normal gastric mucosa sec-
tions at low quantity (detectable exclusively by nested PCR)
(Figs. 2C, 3B,C). These results suggest that, with the exception
of metastasis-specific insertions, many—if not most—insertions
occurred in apparently normal or very early pre-neoplastic cells
and then became fixed during clonal outgrowth. Thus, we specu-
late that if one could obtain the normal parent cell that originally
underwent malignant transformation, that cell would likely con-
tain the somatic insertions present in the tumor.
In contrast, some low abundance insertions have been detect-
ed exclusively by nested PCR in multiple GI tumors, as well as
the one somatic L1 insertion in a TGCT patient (Supplemental
Table 2). Intriguingly, no insertions were verified in the hyperplas-
tic polyp, an adenoma, a colon cancer, the PanIN, two pancreatic
cancers, a lymph node metastasis, two gastric cancers, and seven
Figure 2. PCR and Sanger-sequencing validation scheme of L1-seq results. (A) Multistep PCR validation scheme and location of primers used. Insertions
were primarily validated with conventional PCR at their 3′ junction using the L1Hs with the 3′ primer. Some insertions were also validated with nested PCR
using the “G” primer with a nested 3′ primer. After the 3′ junctionwas located, we attempted to find the 5′ junction using the 5′ primer with L1 out primers.
Triangles symbolize target site duplications (TSD). (B) PCR validation of clonal cancer-specific insertions. (Left panel) A primary colon cancer-and-metas-
tasis-specific insertion (ins. E8). (Right panel) A primary pancreatic cancer-and-metastasis-specific insertion (ins. B7). The higher molecular weight bands
visible above the tumor tissues of the empty site PCR products are the highly truncated L1 elements, as assessed by gel extraction and Sanger sequencing.
(N) Normal, (P) polyp, (C) primary cancer, (C1) primary cancer section 1, (C2) primary cancer section 2, (M) metastasis, (FS) filled site PCR product (in-
sertion allele), (ES) empty site PCR product (wild-type allele). (C) PCR validation of the normal colon-specific insertion “A5n” and the somatic normal-
and-cancer-specific insertion “C1s” in stomach cancer. “A5n” is detectable exclusively using nested PCR in case 2BV, while the somatic L1 insertion in
the stomach cancer of patient 2670 is detectable by both conventional and nested PCR and is also detectable in normal stomach using nested PCR.
(NC) Normal colon, (NL) normal liver, (N1) normal stomach section 1, (N2) normal stomach section 2, (C1) primary cancer section 1, (C2) primary cancer
section 2, (M1) metastasis section 1, (M2) metastasis section 2. O’GeneRuler 1 kb Plus DNA ladder was used (Thermo Scientific). (D) Reconstituted Sanger
sequence of the 5′ truncated colorectal cancer-and-metastasis-specific ins. E8 from B. In blue, TSD (6 bp, alternatively, 7 bp due tomicrohomology at the 5′
junction); in green, highly truncated L1Hs (112/112-bp identity with L1RP, nt 5908–6019); in red, poly(A) tail.
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Figure 3. Representative examples of further somatic L1 insertions in colon cancer patient 2BV and gastric cancer patient 2043. (A) L1 insertions in co-
lorectal cancer (all detectable by conventional PCR), from left to right: ins. D2 (polyp-specific, present exclusively in adenoma sample “5”); ins. A8n (cancer-
and-metastasis-specific, present in three independent primary colorectal cancer sections and in three independent liver metastasis sections); ins. C7 (the
only insertion in colon cancer cases that is detectable in only one tumor section, “6/1”); ins. G5 (a metastasis-specific insertion, present in only one of three
sections of metastasis sample “7”). (N) Normal colon, (P) polyp, (C) primary colorectal cancer, (C1) primary colorectal cancer section 1, (C2) primary co-
lorectal cancer section 2, (C3) primary colorectal cancer section 3, (M) metastasis, (M1) metastasis section 1, (M2) metastasis section 2, (M3) metastasis
section 3, (NL) normal liver. (B) The fifth agarose gel shows the second somatic normal-and-cancer-specific L1 insertion in stomach cancer patient
2043 (detectable in cancer both by conventional and nested PCR, but detectable in normal stomach exclusively by nested PCR). (N1) Normal stomach
section 1, (N2) normal stomach section 2, (C1) primary gastric cancer section 1, (C2) primary gastric cancer section 2. (C) Hematoxylin and eosin
(H&E) staining revealed normal gastric mucosa in case of insertions A2s and C1s (Fig. 2C). (Top, left) Normal gastric mucosa from patient 2043; (top, right)
gastric adenocarcinoma with intestinal differentiation from patient 2043. (Bottom, left) Normal gastric mucosa from patient 2670; (bottom, right) gastric
adenocarcinomawith signet ring features from patient 2670. All photomicrographs were taken at 20× original magnification. H&E-stained slides were sec-
tioned and stained in the Johns Hopkins Department of Pathology according to standard protocols. (D) In order to estimate the limits of detection of an
insertion by conventional and seminested PCR, we performed a dilution series on DNA containing a heterozygous polymorphic germline insertion. Normal
colon DNA containing a polymorphic L1 insertion of patient 4BV was mixed with normal colon DNA of patient 1BV, which did not contain this insertion,
and served as competitor DNA. The amount of DNA used for conventional PCR in the case of 4BVDNA is shown in ng, which is constituted to a final amount
of 25 ng using 1BV DNA. One microliter of each FS PCR product was used for seminested PCR. The detection limit of an insertion using conventional PCR
appears to be 2.5 ng DNA against 22.5 ng competitor DNA (faint PCR band present). However, using seminested PCR, the detection limit is 25 pg DNA
against 24.975 ng competitor DNA. Sanger sequencing confirmed that the lowermolecular weight seminested PCR bands are nonspecific (seen in 1BV and
in 4BV using ≤0.025 ng DNA for conventional PCR, and is marked by an asterisk), while the higher molecular weight band is the correct PCR product
(marked by arrow). Thus, we detect one copy in 10 cells (very faint band) with conventional PCR, and one copy per 1000 cells with seminested PCR.
Identical results were obtained for a second heterozygous polymorphic L1 and a different competitor DNA. O’GeneRuler 1 kb Plus DNA ladder was
used (Thermo Scientific).
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TGCT tumors (Table 1). These latter findings suggest that either a
subset of normal cells lacks somatic L1 insertions and some tumors
arise from these cells, or we merely failed to detect insertions in
some samples.
The presence of early-arising, clonally expanded insertions
raises the possibility that some retrotranspositions are tumor-
initiating events. Importantly, all analyzed cancers displayed
widespread CNVs across their genome, as did the adenoma with
high-grade dysplasia (“10/1”). In contrast, adenomas “5” and
“12” were devoid of any large-scale CNVs (Supplemental Fig. 2b,
d), suggesting a substantial shift in genetic instability occurring
prior to or during the adenoma-carcinoma transition. Notably, ad-
enoma “5” contained a large number of somatic L1 insertions,
leading us to speculate that, in some cases, somatic retrotransposi-
tion may be more important in shaping the early tumor genome
than large CNVs.
Insertions in known or candidate cancer driver genes
The insertions displayed hallmarks of retrotransposition, such as a
poly(A) tail, various sizes of target site duplications (TSDs), 5′ trun-
cations, and inversions (Supplemental Table 2). However, one full-
length insertion (C9) was validated in a colorectal cancer and its
paired metastasis, and one translocation event (C5) was validated
in a liver metastasis of a primary pancreatic cancer. Microhomol-
ogy between the L1 5′ junctions and the unique genomic regions
frequently precluded the precise assessment of the 5′ junction, the
size of the L1 and TSD.
Many of the insertions occurred in known or candidate
cancer driver genes. For example, we verified a primary colorectal
cancer-and-metastasis-specific intronic L1 insertion occurring
within 1.9 kb of two exons of the CYLD gene. CYLD encodes a
de-ubiquitinating enzyme mutated in familial cylindromatosis,
Brooke–Spiegler syndrome, and multiple familial trichoepithe-
lioma type 1. This gene is a known tumor suppressor that is also
somatically mutated in various epithelial cancers and is represent-
ed in the COSMIC Cancer Gene Census (http://cancer.sanger.ac.
uk/census). Another colon cancer had an insertion into the
HDAC9 (histone deacetylase 9) gene which also exhibits a can-
cer-and-metastasis-specific distribution.
Notably, an exonic insertion into a protein coding regionwas
validated in ELOVL4 (ELOVL fatty acid elongase 4) in both sections
of a gastric cancer. Further, a 3′ UTR insertion was validated in
SOX6 (sex determining region Y-box) with nested PCR in a single
pancreatic cancer section. Another 3′ UTR insertion was detected
in STX11 (whose encoded protein plays a role in intracellular
transport) in both sections of the high-grade dysplastic adenoma.
In another adenoma, an intronic L1 was detected in PANX1 (en-
codes for pannexin 1, a gap junction protein). We discovered a
primary pancreatic cancer-and-metastasis-specific intronic inte-
gration event located between two APAF1 exons (apoptotic pepti-
dase activating factor 1) 700 bp downstream and 1 kb upstream,
respectively. APAF1 is a component of the apoptosome that is
dysregulated in pancreatic ductal adenocarcinomas (Corvaro
et al. 2007). In another pancreatic cancer patient, an intronic L1
in the GDNF gene was also present in both the primary cancer
and its metastasis. GDNF is a glial cell line-derived neurotrophic
factor and a ligand of RET, which has been suggested to participate
in pancreatic cancer progression and invasion (Zeng et al. 2008).
Intronic L1 insertions were likewise found in stomach tumors in
the cancer driver candidate genes KLF12 (Kruppel-like factor 12),
a known player in gastric cancer progression (Nakamura et al.
2009), and in CTNND2, which encodes for catenin delta 2.
Together with our results, cell adhesion and neuronal genes
have repeatedly been reported to be excessively mutagenized by
somatic L1 insertions in cancer (Iskow et al. 2010; Lee et al.
2012; Solyom et al. 2012; Ewing et al. 2013; Shukla et al. 2013;
Cooke et al. 2014; Helman et al. 2014; Tubio et al. 2014), and
some genes seem to act as hotspots for insertions. Intriguingly,
CNTNAP2 (contactin associated protein-like 2, a member of the
neurexin family with cell adhesion functions in the nervous sys-
tem) has been recurrently mutagenized by L1 insertions in four
lung and an endometrial carcinoma (Helman et al. 2014; Tubio
et al. 2014).We also found two independent somatic L1 insertions
in this gene in gastric cancer patient 2043. One of these insertions
simultaneously targeted the MIR548I4 gene that is located within
the primary transcript of CNTNAP2. Likewise, we found a somatic
L1 insertion in a stomach cancer in RIMS2 (regulating synaptic
membrane exocytosis 2). RIMS2 was found to be a target for inser-
tionalmutagenesis also by others (Lee et al. 2012) in head andneck
squamous cell carcinoma, as well as in colon cancer. However, we
did not observe any general enrichment of cancer driver or cell ad-
hesion genes targeted by somatic L1 insertions when compared to
germline insertions (data not shown).
L1 insertions and protein expression
We assessed the impact of somatic L1 insertions on the expression
of the corresponding protein-coding genes by comparing pro-
tein abundance across the entire proteome of the polyp with
the highest number of somatic L1 insertions (sample “10”)
with that of its paired normal colon (sample “8”) using mass
spectrometry analysis. Of the nine validated somatic insertions
that were in protein coding regions in the polyp (Supplemen-
tal Table 2), two proteins—KIAA1217 and WARS2—were down-
regulated in the adenoma >90% and >70%, respectively (Supple-
mental Fig. 3; Supplemental Table 5). Of 3025 proteins analyzed,
989 (32%) were down-regulated greater than or equal to twofold
and 804 (26%) were down-regulated at least as much as WARS2.
Among the 3025 proteins analyzed, only KIAA1217 and WARS2
were represented in nine genes with validated somatic L1 inser-
tions. If one picks two genes that are expressed, one would expect
both to be down-regulated 0.274 × 0.274 or 0.07 of the time.
Thus, although it is quite possible that the intronic insertions
in these two genes led to the decrease in their protein abundance,
7% of the time these two genes would be down-regulated by
chance alone. Additional genetic, epigenetic, or post-transcrip-
tional/post-translational changes affecting either allele cannot
be ruled out. Thus, we cannot conclude from these results that
the decrease in protein levels is due to the L1 insertions. Interest-
ingly, KIAA1217 was previously insertionally mutagenized by an
L1 in a colorectal cancer (Lee et al. 2012), andWARS2 was mutat-
ed by a processed pseudogene insertion in a chondrosarcoma
(Cooke et al. 2014).
Discussion
We provide evidence that somatic retrotransposition events are an
abundant source of endogenous mutagenesis in human GI tissues
and that their presence in precancers is the likely result of clonally
expanded normal/non-neoplastic precursor cells in which the in-
sertions become fixed (Fig. 4). Of note, the clonal outgrowth of a
cell containing a somatic insertion increases the ability to detect
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insertion events independent of these insertions being drivers
of tumorigenesis. Our findings agree with a recent mathematical
model predicting that at least half of the somatic mutations in
cancers arising in self-renewing tissues originate prior to tumori-
genesis (Tomasetti et al. 2013). Previously, we hypothesized that
a larger fraction of insertions occurred late during tumorigenesis,
but at that time, we did not study dissected cancers and precancers
(Solyom et al. 2012).
Our number of tumor-specific retrotransposon insertions is
an underestimate because (1) only L1Hs, andnot other types of ret-
roelement insertions, were examined; (2) long 3′ transductions
and insertions truncated 3′ to the diagnostic L1Hs nucleotides
are missed by L1-seq; and (3) detection of insertions is bound
by the sensitivity and specificity of L1-seq and PCR validation
(Fig. 3D). Furthermore, the number of somatic normal-specific
insertions was likely underestimated, as tumors are invariably con-
taminated by normal cells; thus, somenormal tissue-specific inser-
tions are likely scored as germline by L1-seq.
Although it has been accepted that classical mutations can
cause cancer, functional studies on somatic tumor-specific retro-
transposon insertions are lacking. Since retrotransposon insertions
are large, abundant, and can be extremely disruptive to gene func-
tion, as evidenced by more than 100 germline disease-causing
retroelement insertions in humans (Hancks and Kazazian 2012),
they have the potential to initiate and aggravate tumorigenesis
in somatic cells. Thus, the questions are: How large a fraction of
these L1 insertions are drivers of dysplasia and/or subsequent
cancer progression?Howmany contribute to genetic instability in-
directly, e.g., by providing templates for homologous recombina-
tion, transcriptional interference, alternative splicing, epigenetic
effects, or the generation of DNA double-strand breaks (Goodier
and Kazazian 2008)? Since retrotransposition appears to be mostly
a random process, somatic insertions are private mutations, and a
portion of these could account for cancer cases for which causative
recurrent mutations have not been identified.
Previously, evidence for L1 insertions in normal somatic cells
has come from two sources. A number of studies have shown that
somatic L1 insertions occur in neuronal development and are
present in various sites in the human and mouse brain (Muotri
et al. 2005; Coufal et al. 2009; Baillie et al. 2011; Evrony et al.
2012; Upton et al. 2015). Moreover, a small number of examples
of L1, SVA, and processed pseudogene insertions have been report-
ed to occur in early humandevelopment (vandenHurk et al. 2007;
de Boer et al. 2014; Vogt et al. 2014). Now, we have definitive ev-
idence for somatic L1 retrotransposition in normal colonic and
gastric tissues.
Our results suggest the need for a shift of attention to inser-
tion (mutation) timing, as it could be normal-appearing cells
that harbor tumor-initiating genetic lesions. It would be extremely
valuable if we could identify those cells that appear normal but are
alreadymolecularly committed to becoming dysplastic, particular-
ly in patients at risk for nonresectable tumors. However, identifica-
tion of these apparently normal cells by sequencing normal and
tumor tissues will be problematic, since tumor-initiating normal-
appearing cells likely become part of the tumor, and even micro-
dissected tumors are contaminated with normal cells, making it
difficult to distinguish insertions in tumor vs. contaminating
normal cells. Although we did not find normal tissue-specific in-
sertions (Fig. 4A) that were detectable by conventional PCR, such
insertions may exist whose detection could depend on the
amount of input DNA used for genotyping and the fraction of
cells containing the insertion. This possibility raises questions re-
garding our TGCT insertion and insertions in previous studies us-
ing blood as the normal tissue (Lee et al. 2012; Ewing et al. 2013;
Cooke et al. 2014; Helman et al. 2014; Tubio et al. 2014). That is
to say, these insertions were not verified in the same normal tis-
sue from which the tumor originated, or in other words, the na-
ture of tumor-specificity versus simply normal tissue-specificity
of the insertions is not known. Especially using nested PCR,
one may misdiagnose some insertions as tumor-specific, when
in reality they may be due to contamination from normal tissue.
This problem arises because of the exquisite sensitivity of next-
generation sequencing and is now detected by improved valida-
tion efforts (Supplemental Fig. 2d). However, the problem disap-
pears when one finds somatic L1 insertions in primary cancers
and their metastases to another tissue or organ, due to clonality.
In future studies, it may be important to include normal samples
of the same tissue type in which the tumor is located, use tissue
microdissection, and single-cell sequencing. Especially using sin-
gle-cell analysis, it will be interesting to learn whether somatic
retrotransposition is widespread in many human tissues and
whether the rate of somatic retrotransposition is increased in can-
cer (see Goodier 2014).
To summarize, numerous genes and intergenic regions are
targeted by hundreds of somatic L1 insertions very early during
GI, but not testicular tumorigenesis, indicating the preference of
somatic retroelementmovement in epithelial tumors. Our data in-
dicate that somatic retrotransposition occurs very early during the
development of most GI cancers. We suggest that many somatic
insertions discovered in various cancers have their origin in a his-
tologically normal cell and that one or more of the somatic retro-
transpositions in that normal cell may lead to its selection for
cancer development.
Figure 4. Distribution of somatic L1 insertions. (A) Normal colon crypt
containing a few cells with L1 insertions (detectable only by nested PCR).
(B) Colon tumor with early L1 insertions (detectable by conventional
PCR). (C ) L1 insertions occurring late during tumorigenesis (detectable
only by nested PCR). (D) Colon tumor containing early L1 insertions with
contaminating normal cells (detectable only by nested PCR). Note that
by using nested PCR, it may be possible to misdiagnose contaminating
or tumor-invading normal tissue-specific insertions (A) as tumor-specific
(C or D). The frame represents the sampled tissue.
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Methods
Human DNA samples
All samples were fresh-frozen. GI tissues were acquired from Johns
Hopkins University, Baltimore (IRB# NA_00092914). Non-neo-
plastic tissues were dissected away from the neoplastic cells of
colorectal, pancreatic, and stomach cancer patients to maximize
neoplastic cell cellularity. DNA from these tissues was extracted us-
ing the AllPrep DNA/RNA Mini kit (Qiagen) after disruption and
homogenization with a rotor-stator homogenizer. The TGCT sam-
ples with >75% tumor cells and matched peripheral blood were
collected at Erasmus MC, The Netherlands. DNA-isolation of
TGCTs and blood was done using the AllPrep DNA/RNA Mini kit
(Qiagen).
L1-seq library construction, sequencing, and analysis
The sequencing libraries for L1Hs elements were constructed using
L1-seq as previously described (Ewing and Kazazian 2010; Solyom
et al. 2012). Briefly, this method amplifies the 3′ flanking regions
of L1Hs elements using hemi-specific PCR. PCR-amplified L1Hs
element insertion site junctions were TOPO-TA cloned (Invitro-
gen) and Sanger-sequenced for quality control of the library prep-
aration and were subsequently sequenced on an Illumina HiSeq
2500 at the Johns Hopkins University Genetic Resources Core
Facility High Throughput Sequencing Center. Sequence results
were analyzed as previously described (Solyom et al. 2012). Python
scripts used for the mapping and primary analysis are available in
the SupplementalMaterial and at https://github.com/adamewing/
l1seq. Overall mapping statistics and sensitivity estimates for
each pooled library are presented in Supplemental Table 1. Refer-
ence insertions are defined as those with an L1Hs present in
hg19/GRCh37 in the proper position (<500 bp from the peak)
and orientation for a given cluster of aligned reads. Reference inser-
tion sites are cataloged in Supplemental Table 4a–d. Nonreference
germline insertions are defined as those present in every sample
of the particular patient and represented by greater than 50 total
reads, at least two unique read alignments, and not corresponding
to a known L1Hs or L1PA element in the hg19/GRCh37 assembly.
Putative nonreference insertions and overlapwith previous studies
in which nonreference L1 insertions have been cataloged are pre-
sented in Supplemental Table 3a–d.
Based on the validation results (see “PCR validation of the
Illumina results”), successful and unsuccessful validations (valida-
tion failures) were used to predict the number of untested sites
likely to validate using a conditional inference tree (Hothorn
et al. 2006) as implemented by the “ctree” function in the “party”
package available for the R statistical computing environment
(R Core Team 2015). Conditional inference trees were generated
separately for the colorectal, pancreatic, and stomach cancer cases
(Supplemental Fig. 1). Validation status (1/0 for pass/fail) was used
as the dependent variable, and the following peak characteristics
were used as the independent variables: number of reads (max-
count), number of unique reads (maxuniq), span of alignments
(width), mapping quality (mapq). The likelihood of a given inser-
tion validating can be estimated by examining the partitions as-
signed by the conditional inference tree shown in Supplemental
Figure 1 and following the branches of the tree to one of the termi-
nal nodes. In order to obtain a rough estimate of the number of in-
sertions that might validate from the total number of untested
insertions in our data set, we applied this logic to all putative inser-
tions with mapscore > 0.17 (average mappability score) and map-
ping quality of at least 12 (based on Bowtie 2 output mapping
scores) (Langmead and Salzberg 2012). The cutoffs for untested
pancreatic insertion sites weremapscore > 0.44 andmapping qual-
ity > 20.53. The cutoffs for untested gastric insertion sites were
mapscore > 0.5 and mapping quality > 10. Cutoffs for each experi-
ment differ, because they are based on the minimum values for
mapscore and mapping quality for validated insertions in our
data. Theseminimumvalues vary between experiments due to dif-
fering characteristics across libraries (Supplemental Table 1) and
differences in the validation strategy across experiments (Sup-
plemental Table 2f–s). The number of untested insertions falling
into each validation bin (i.e., terminal node on the conditional in-
ference tree) was multiplied by the likelihood for that bin, and
then multiplied by the tissue-specific validation rate based on
the combination of tissue types in which the insertion was detect-
ed. It should be noted as a caveat that validation was mostly per-
formed on insertions deemed likely to validate based on peak
and sample characteristics (e.g., high number vs. low number of
reads, cancer-and-metastasis-specific vs. metastasis-only putative
insertions), so extrapolation of smaller peak sizes is less reliable.
Data used to generate conditional inference trees and untested
sites are available as Supplemental Table 2, and results are shown
in Table 1.
PCR validation of the Illumina results
A multistep PCR validation protocol was used to validate L1-seq
reads and to retrieve 3′ and 5′ junctions. As the first step, L1 3′
ends together with flanking genomic regions were amplified using
the same diagnostic L1Hs-specific “AC” di-nucleotide primer as
used for L1-seq (GGGAGATATACCTAATGCTAGATGACAC) and
a primer selected from the 3′ flanking region based on the refer-
ence genome sequence (3′ primer). PCR reactions were carried
out in 12.5 µL 2×GoTaqGreenmastermix (Promega) in a total vol-
ume of 25 µL, with 0.8 µL of 3′ primer, 1.5 µL of L1Hs primer, and
25 ngDNA to amplify the filled site. The empty site (WT allele) was
amplified with the same conditions, except that 1.5 µL of 3′ prim-
er, 1.5 µL of 5′ primer (selected from the 5′ flanking region based
on the reference genome sequence), and 12.5 ng DNA were used.
Primers were 20 pmol/μL and their location is depicted in Figure
2A. Reactions were incubated for 2min at 95°C, followed by 30 cy-
cles of 30 sec at 95°C, 30 sec at 57°C, and 1.5min at 72°C, followed
by final extension of 5 min at 72°C on a Bio-Rad T100 Thermal
Cycler. In some GI cases, nested PCR was used on 1 µL of filled
site PCR product using the same L1Hs diagnostic “G” primer
that was used for L1-seq (TGCACATGTACCCTAAAACTTAG), to-
getherwith a 3′ nested primer for another 30 cycles.Whennonest-
ed primer was available, seminested PCR was performed using the
“G” primer together with the original 3′ primer. Long-range PCR
to recover longer L1 insertions was performed with the Expand
Long Template PCR System (Roche) according to the manufactur-
er’s instructions in buffer 1, with 1 µL of 20 µM 3′ and 5′ primers
each, and 25 ng DNA. 5′ junctions were PCR-amplified using the
same conditions as for the 3′ junction, except that a primer hybrid-
izing to the L1 5′ UTR was used (L1nt112out: GATGAACCCGGTA
CCTCAGA) together with the respective 5′ primer, and primer
extension time was only 45 sec, or the “GTG” primer (reverse
complement of the L1Hs-specific “AC” primer) was used with
the 5′ primer using conventional or long-range PCR conditions.
3′ and 5′ primer sequences are included in Supplemental Table
2. PCR products were cut out of the gel, extracted with a QIAquick
Gel Extraction kit (Qiagen) and Sanger-sequenced. See Supple-
mental Data 1–4 for Sanger sequence data. Insertions in pancreatic
and stomach cancer cases were either PCR-validated from gDNA
or from genome-amplified DNA that was produced using the
REPLI-g Mini kit (Qiagen) with Multiple Displacement Amplifica-
tion (MDA). Results on gDNA and MDA-amplified DNA were
identical.
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Human SNP Array 6.0 experiments
The following genomic DNAs from the four colorectal cancer pa-
tients were analyzed: 1BV “1” and “3/1”; 2BV “20” (normal liver),
“5”, “6/1”, and “7”; 3BV “15” (another section of normal colon)
and “10/1”; 4BV “11”, “12”, “13”, and “14”. Patient codes are ex-
plained in Supplemental Table 2, except for samples “20” and
“15”, when a new sample was used, and their source is specified
in parentheses. These DNAs were analyzed for concentration and
quality with the Agilent 2100 Bioanalyzer (Agilent Technologies).
The samples then underwent digestion, amplification, andhybrid-
ization to an Affymetrix Human SNP 6.0 Array, comprising over
1.8 million markers, as per the manufacturer’s protocol. In short,
DNAaliquotswere digestedwith StyIDigestionMastermix, ligated
to Sty primers and PCR-amplified. The process was repeated with
NspI restriction enzyme, and the products were pooled and
bead-purified. After quantification, the samples were fragmented
and labeledwith biotin. Samples were hybridized to the SNP arrays
at 50°C for 16 h at 60 rpm, after which the arrays were transferred
to the Affymetrix GeneChip Fluidics Station 450 for antibody
staining and washing. The washed arrays were scanned with
the Affymetrix GeneChip Scanner 3000 7G as per protocol, and
data in the form of CEL and CHP files were extracted with the
Affymetrix Genotyping Console (www.affymetrix.com). These
raw data were imported for copy number analysis into the Partek
Genomics Suite v6.6 platform (Partek Inc.). Partek’s standard pro-
tocol was used to estimate copy number changes, for each of 1.8
millionmarkers, for each patient’s polyp, primary, and/ormetasta-
sis cancer samples as compared to that patient’s control sample.
Partek’s Genomic Segmentation analysis was used to identify
regions of copy number variation by looking for blocks of 20 or
more genomic markers showing P-value thresholds of <0.001,
minimal signal to noise ratios of 0.3, and a range of diploid copy
number cut-off thresholds. For the macroscale CNV analysis,
Partek was used to generate ideograms indicating CNV status,
increase or decrease, at the various thresholds. Individual SNP ge-
notypes were determined from the Affymetrix CHP files exported
by their Genotyping Console using the Birdseed algorithm (Korn
et al. 2008).
Quantitative proteomic analysis
For proteomic analysis, we processed a new section of sample “10”
(tumor, highest number of somatic L1 insertions) and matched
sample “15” (normal colon, no somatic L1 insertions detected).
Although, the original sample “10” was first classified as a cancer,
and subsequently as an adenoma with high-grade dysplasia, the
new section used for proteomics was adenomawith low-grade dys-
plasia. Frozen OCT tissues were first cryo-pulverized in the pres-
ence of liquid nitrogen. Powderized tissue samples were then
homogenized to extract proteins using a lysis buffer (4% SDS,
100 mM Tris, pH 7.6). Crude protein extracts were further sonicat-
ed before centrifugation at 2500g for 10 min at room temperature.
Supernatant protein lysates were then transferred to a 1.5-mL tube
for another centrifugation at 12,000g for 10 min. Cleared protein
lysates were used for proteomic analysis. As described previously
(Wisniewski et al. 2009; Kim et al. 2014), a total of 250 μg proteins
were transferred to a 10-kDa filter unit, centrifuged at 12,000g
for 10 min, reduced using 10 mM dithiothreitol at 60°C for 30
min, centrifuged to exchange to a urea buffer (8 M urea, 20 mM
HEPES, pH 8.0), and alkylated with 10 mM iodoacetamide for 30
min in the dark. After centrifugation, urea concentrationwas dilut-
ed to <2 M, and proteins were digested with trypsin at an enzyme-
to-protein ratio of 1:20 for 16 h at room temperature. Peptideswere
collected in filtrates by centrifugation at 12,000g, desalted using
a Sep-Pak C18 cartridge, vacuum-dried, and labeled with TMT
reagents (126, 127, 128, and 129) following the manufacturer’s
instructions. Four labeling reactions were carried out, including
a replicate. Labeled peptides were mixed and fractionated using
reverse phase liquid chromatography at pH 10 into 24 fractions.
Each fraction was analyzed separately on a high-resolution Orbi-
trap Fusion mass spectrometer (Thermo) online connected with
a high-pressure EASY-nLC 1000 liquid chromatography system
(Thermo). Peptides were loaded onto a trap column and separated
in a 250-nL/min nanoflow rate with a linear gradient of acetoni-
trile (7% to 35%). Precursor ions selected were fragmented by a
higher energy C-trap dissociation method, and MS3 scans were
sequentially acquired by utilizing synchronous precursor selection
technology (Ting et al. 2011). Raw mass spectrometry data were
analyzed on a Proteome Discoverer platform (version 1.4) using
the Sequest database searching algorithm with the following pa-
rameters: up to 2 missed cleavages allowed, full trypsin digestion
only considered, N-termini and lysine fully labeled with TMT re-
agent, oxidation at methionine allowed, peptide tolerance within
7 ppm, and fragment tolerance within 0.05 Da. Peptide identifica-
tion was considered by applying peptide-spectrum matches with
<1% false discovery rates. Quantification values were calculated
by Proteome Discoverer.
Data access
The L1-seq data from this study have been submitted to the NCBI
database of Genotypes and Phenotypes (dbGaP; http://www.ncbi.
nlm.nih.gov/gap/) under study accession number phs000536.v3.
p1. The SNP array data have been submitted to the NCBI Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/)
under accession number GSE63601. The proteomics data have
been submitted to the PRoteomics IDEntifications database
(PRIDE; http://www.ebi.ac.uk/pride/archive/) under accession
number PXD001626.
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